News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pluristem Therapeutics (PSTI) Move Forward In The Orthopedic Area With The Support Of Key Opinion Leaders



5/29/2014 9:07:08 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

HAIFA, Israel, May 29, 2014 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PLTR), a leading developer of placenta-based cell therapies, today announced it has enhanced its activity in the orthopedic indications for its PLacental eXpanded (PLX) cell therapies. In January, Pluristem announced positive results from its Phase I/II clinical trial for the treatment of injured gluteal muscle after total hip arthroplasty (THA). "This is a great result for a long path from a first idea to such a success in a first-in-men study in orthopedics with an off-the-shelf product to allow muscle regeneration," states Dr. Georg Duda, the Director of the Julius Wolff Institute and Berlin-Brandenburg Center for Regenerative Therapies at the Charité, Berlin. "This is the first hope for muscle regeneration with virtually no clinical therapy presently available to treat injuries or defects in shoulder or lower leg muscles," added Dr. Carsten Perka, Head of Orthopedics at the Center for Musculoskeletal Surgery at the Charité, Berlin.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES